Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy

European Journal of Medical Research

Volumn 10, Issue 4, 2005, Pages 155-160

  Götz, Angela K ^a   Boger C A ^a   Hirschmann, C ^a   Schmitz, G ^a   Riegger, G A J ^a   Kramer B K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Diabetic nephropathy; Dialysis; HMG CoA Reductase Inhibitors; Nephropharmacology; Survival

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; GERMANY; HEMODIALYSIS; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

AGED; CHOLESTEROL, LDL; CHRONIC DISEASE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17844365882     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Baigent C, Landray M, Warren M (2004) Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Curr Opin Nephrol Hyperten 13: 601-605
2. Wanner C, Krane V, März W, Olschewski M, Asmus H-G, Krämer W, Kühn K-W, Kütemeyer H, Mann JFE, Ruf G, Ritz E (2004) Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics. Kidney Blood Press Res 27: 259-266
3. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H (1992) Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41: 81653-81661
4. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J (1992) Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41: 81394-81399
5. Seliger SL, Stehman-Breen CO (2003) Are HMG-CoA Reductase Inhibitors Underutilized in Dialysis Patients? Semin Dialy 16 (3): 179-185
6. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 13: 81918-81927
7. Harris K, Thomas M, Short C, Moore R (2002) Assessment of the efficiency of treatment of dyslipidemia in renal outpatients. J Nephrol 15: 8263-8269
8. American Diabetes Association (2004) Dyslipidemia management in adults with diabetes. Diabetes Care. 27: 68-71
9. Grundy AM, Cleeman JI, Merz CNB, Brewer HB Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr., Stone NJ (2004) Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 24:e149-e161
10. Böger C, Götz A, Stubanus M, Banas B, Deinzer M, Krüger B, Holmer SR, Schmitz G, Riegger GAJ, Krämer BK (2005) C-Reactive Protein as predictor of death in end stage diabetic nephropathy: role of peripheral aterial disease. Kidney Int (In press)
11. Hoenich NA, Katopodis KP (2002) Clinical characterization of a new polymeric membrane for use in renal replacement therapy. Biomaterials, 23: 3853-8
12. Dupont WD, Plummer WD Jr (1990) PS power and sample size calculations. A review and computer program. Controlled Clin Trials. 11: 116-28
13. Fellström BC, Holdaas H, Jardine AG (2003) Why do we need a statin trial in hemodialysis patients? Kidney Int 63 (84): S204-S206
14. Ishani A, Herzog CA, Collins AJ, Foley RN (2004) Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Kidney Int 65: 1017-1025
15. Lowrie E, Lew N (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 8458-8482
16. Attman P-O, Samuelsson O, Johansson A-C, Moberly JB, Alaupovic P (2003) Dialysis modalities and dyslipidemia. Kidney Int Suppl. 84: 110-112
17. Wanner C, Krane V (2002) Uremia-Specific Alterations in Lipid Metabolism. Blood Purif 20: 451-453
18. Liebl A, Mata M, Eschwege E (2002) Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 45: 23-28
19. Viola RA, Abbott KC, Welch PG, McMillan RJ, Sheikh AM, Yuan CM (2002) A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrology 3: 9
20. Sica DA, Gehr TW (2002) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Curr Opin Nephrol Hypertens 11 (2): 123-133
21. Navaneethan S, Shrivastava R (2004) HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 18(4): CD004289
22. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297-304
23. Girndt M, Heisel O, Köhler H (1999) Influence of dialysis with polyamide vs hemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant, 14: 676-82
24. Norcini JJ, Lipner RS, Kimball HR (2002) Certifying examination performance and patient outcomes following acute myocardial infarction. Med Educ. Sep;36(9): 853-9
25. Frimat L, Loos-Ayav C, Panescu V, Cordebar N, Briancon S, Kessler M (2004) Early referral to a nephrologist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease. Diabetes Metab. Feb;30(1):67-74
26. Iseki K, Yamazato M, Tozava M, Takishita S (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61: 81887-81893
27. Avram M, Mittman N, Bonomini L, Chattopadhyay J, Fein P (1995) Markers for survival in dialysis: a seven-year prospective study. Am J Kidney Dis 26: 8209-8219
28. Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, Timio M (2003) Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. J Nephrol 16(2): 245-251
29. Bologa R, Levine D, Parker T, Cheigh J, Serur D, Stenzel K, Rubin A (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 8107-8114
30. Fernandez-Reyes MJ, Alvarez-Ude F, Sanchez R, Mon C, Iglesias P, Diez JJ, Vazques A (2002) Inflammation and malnutrition as predictors of mortality in patients on hemodialysis. J Nephrol 15(2): 136-43
31. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G (2004) Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transpl 19: 1507-1519